Literature DB >> 25257076

Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey.

Eric Bruckert1, Samir Saheb2, Juliette Roth Bonté3, Carole Coudray-Omnès3.   

Abstract

Homozygous familial hypercholesterolaemia (HoFH) is a rare and severe hereditary lipid disorder that is typically associated with high serum levels of low-density lipoprotein cholesterol (LDL-C). Excessive exposure to high levels of LDL-C puts affected individuals at very high risk of premature onset coronary heart disease, and this considerably limits life expectancy. Although the clinical features and treatment of HoFH have been extensively researched, societal and socio-psychological impacts of the disease have not been reported to date. The current study was conducted to investigate the burden of disease and treatment from the patient's perspective by means of semi-structured interviews with 24 HoFH patients. The findings of the survey indicate that HoFH represents a considerable burden for patients, not only due to physical signs and limitations caused by the disease but also a number of psychosocial factors, treatment-related issues and impact on their education and employment situation.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Burden of disease; Homozygous familial hypercholesterolaemia; Patient survey; Psychosocial factors

Mesh:

Substances:

Year:  2014        PMID: 25257076     DOI: 10.1016/j.atherosclerosissup.2014.07.006

Source DB:  PubMed          Journal:  Atheroscler Suppl        ISSN: 1567-5688            Impact factor:   3.235


  8 in total

Review 1.  The panorama of familial hypercholesterolemia in Latin America: a systematic review.

Authors:  Roopa Mehta; Rafael Zubirán; Alexandro J Martagón; Alejandra Vazquez-Cárdenas; Yayoi Segura-Kato; María Teresa Tusié-Luna; Carlos A Aguilar-Salinas
Journal:  J Lipid Res       Date:  2016-10-24       Impact factor: 5.922

2.  Exercise tolerance and quality of life in patients with known or suspected coronary artery disease.

Authors:  Vasiliki Katsi; Georgios Georgiopoulos; Panagiota Mitropoulou; Konstantinos Kontoangelos; Zoi Kollia; Chara Tzavara; Dimitrios Soulis; Konstantinos Toutouzas; Dimitrios Oikonomou; Alberto Aimo; Konstantinos Tsioufis
Journal:  Qual Life Res       Date:  2021-04-24       Impact factor: 4.147

3.  Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia.

Authors:  Axel C Mühlbacher; Andrew Sadler; Franz-Werner Dippel; Christin Juhnke
Journal:  Pharmacoeconomics       Date:  2018-04       Impact factor: 4.981

4.  Cohort Generation and Characterization of Patient-Specific Familial Hypercholesterolemia Induced Pluripotent Stem Cells.

Authors:  Linda Omer; Elizabeth A Hudson; Lisa C Hudgins; Nolan L Boyd
Journal:  Stem Cells Dev       Date:  2021-05-21       Impact factor: 4.390

5.  Management of homozygous familial hypercholesterolaemia in two brothers.

Authors:  José Real; Cristina Arbona; Rosa Goterris; Juan Francisco Ascaso
Journal:  BMJ Case Rep       Date:  2018-01-06

Review 6.  Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.

Authors:  Claudia Stefanutti
Journal:  Curr Atheroscler Rep       Date:  2020-06-18       Impact factor: 5.113

7.  Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia.

Authors:  Tawfeg Ben-Omran; Luis Masana; Genovefa Kolovou; Gema Ariceta; F Javier Nóvoa; Allan M Lund; Martin P Bogsrud; María Araujo; Osamah Hussein; Daiana Ibarretxe; Rosa M Sanchez-Hernández; Raul D Santos
Journal:  Adv Ther       Date:  2019-05-17       Impact factor: 3.845

Review 8.  LDL Apheresis and Lp (a) Apheresis: A Clinician's Perspective.

Authors:  Meral Kayikcioglu
Journal:  Curr Atheroscler Rep       Date:  2021-02-17       Impact factor: 5.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.